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Intravascular  lymphomatosis  (IVL)  is a rare  subtype  of  lymphoma  characterized  by proliferation  of  lym-
phoma  cells  into  small  vessels.  Clinical  presentations  of  IVL are  considerably  varied  among  patients,  and
antemortem  diagnosis  is sometimes  difﬁcult.  We report  a 75-year-old  Japanese  female  who  presented
with  gradually  worsening  shortness  of  breath  and  pulmonary  hypertension.  After  routine  examinations,
the  patient  was  diagnosed  with  pulmonary  artery  hypertension  (PH)  combined  with  pulmonary  hyper-
tension  owing  to left-sided  heart  disease  possibly  due  to chronic  atrial  ﬁbrillation.  However,  a  standard
therapy  of PH and  diuretics  was  ineffective.  In  the  clinical  course,  sustained  increase  in  serum  lactate
dehydrogenase  level,  progressive  bicytopenia,  and  appearance  of  atypical  cells  in her peripheral  blood
led  to the diagnosis  of  IVL.  The  symptoms,  laboratory  ﬁndings  and  PH  improved  after  initial  chemotherapy.
<Learning  objective:  Pulmonary  artery  hypertension  (PH)  has  been  focused  in cardiovascular  diseases
and  considerable  progress  in diagnosis  and  treatment  was  achieved.  The  targets  of  the  treatment  are  PH
and underlying  causes  of  PH.  The  prevalence  and frequency  of  the  underlying  causes  extensively  vary.
However,  considering  that  PH  is  a progressive  and  fatal  disease  if untreated,  sufﬁcient  evaluation  and
optimal  treatments  are  essential.  Intravascular  lymphomatosis  might  be considered  to  have  a potential
to  cause  PH.>
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Pulmonary hypertension (PH) is a progressive and fatal dis-
ase, if untreated. To date, considerable progress has been achieved
egarding diagnosis, classiﬁcation [1], and treatment. However, the
nderlying causes of PH are extensively varied, with some diseases
ess known than others. We  report a rare case with PH presumably
aused by intravascular lymphomatosis (IVL), which required skin
iopsy to conﬁrm the diagnosis.
ase report
A 75-year-old Japanese female was admitted to our hospi-
al presenting with progressive shortness of breath on exertion.
he had a history of atrial ﬁbrillation 5 years before admission
nd depression. When she was diagnosed with atrial ﬁbrillation,
chocardiography showed normal left ventricular systolic function
nd mild tricuspid regurgitation (TR) with TR pressure gradient
TR-PG) of 32 mmHg. She was a current smoker with one pack
f cigarettes per day for 20 years. Nine months before admission,
he noticed shortness of breath on exertion. The symptoms had
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gradually worsened before she was admitted for further evalua-
tion and treatment. Physical examination was as follows: blood
pressure 116/64 mmHg, heart rate 77/min, and oxygen satura-
tion on room air 95%. Increased pulmonic second heart sound
and no abnormal respiratory sounds were auscultated. Jugu-
lar venous distention and slight bilateral pretibial edema were
found. Chest X-ray showed enlargement of second right arch with
increased cardiothoracic ratio (Fig. 1, left panel). Electrocardio-
gram showed atrial ﬁbrillation and negative T wave in precordial
leads. Blood examinations showed mild anemia, increased lev-
els of lactate dehydrogenase (LDH) (hemoglobin, 10.8 mg/dL; LDH,
1268 mU/mL) with normal values of markers related to connec-
tive tissue diseases. Pulmonary function test showed a reduction
of single breath diffusing capacity (diffusing capacity for carbon
monoxide, 62%; % volume capacity, 88%; % forced expiratory vol-
ume  in 1 s, 73%). Echocardiography showed no left-sided heart
diseases, but elevated right-sided heart pressure with TR-PG of
61.2 mm Hg (Fig. 2, left panel). Multi-detector computed tomo-
graphy revealed no ﬁlling defects of pulmonary artery or other
pulmonary diseases. Ventilation-perfusion lung scanning showed
no evidence of chronic thromboembolic pulmonary hypertension.
Right heart catheterization showed elevated pulmonary artery
pressure (mean, 31 mmHg), pulmonary capillary wedge pressure
(mean, 16 mmHg), and pulmonary vascular resistance (262 Dyne-
s-cm-5) with normal range of cardiac index. Based on these data,
vier Ltd. All rights reserved.
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Fig. 1. (Left panel) Chest X-ray on admission showed enlargement of second right arch with increased cardiothoracic ratio. (Right panel) Chest X-ray after treatment for
intravascular lymphomatosis showed no remarkable difference from that on admission.
F y hypertension. The pressure gradient of tricuspid regurgitation (TR-PG) was 61.2 mmHg.
( owed a reduction in TR-PG.
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pig. 2. (Left panel) Transthoracic echocardiography shows marked pulmonary arter
Right  panel) Echocardiography after treatment for intravascular lymphomatosis sh
he was diagnosed with idiopathic PH (Group 1 of the Dana Point
lassiﬁcation) combined with PH owing to left-sided heart dis-
ase possibly due to chronic atrial ﬁbrillation (Group 2 of the Dana
oint Classiﬁcation). On the basis of the diagnosis, we  adminis-
ered ambrisentan, tadalaﬁl, beraprost, and diuretics at the same
ime. However, her symptoms showed no improvement after
reatment. In addition, serum LDH level remained high, and she
equired blood transfusion for rapidly progressive anemia. We
ithdrew ambrisentan fearing that the erythrocytopenia was an
dverse effect of the drug. Despite drug withdrawal, leukocytopenia
ppeared in addition to the erythrocytopenia. Moreover, 1 month
fter the treatment, atypical cells appeared in her peripheral blood,
hich prompted us to examine hematological diseases. Bone mar-
ow biopsy showed inﬁltration of lymphoma cells. Random skin
iopsy revealed remarkable inﬁltration of lymphoma cells into
mall vessels (Fig. 3), which ﬁnally led to the diagnosis of IVL.
he inﬁltration of B cell lymphoma into pulmonary vessels was
uspected to be the cause of PH. After the ﬁrst course of chemother-
py, despite no remarkable change in the chest X-ray (Fig. 1, right
anel), modest improvement was observed in her symptoms and
Fig. 3. Skin biopsy revealed remarkable inﬁltration of lymphoma cells into small
vessels (hematoxylin–eosin stain).
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ormalization of serum LDH level accompanied by a reduction in
R-PG from 61.2 to 48.4 mmHg  (Fig. 2, right panel).
iscussion
We  experienced a rare case of IVL presenting with PH, although
he treatment of PH was unsuccessful. Detection of atypical lym-
hocytes in the peripheral blood, as well as sustained increase in
erum LDH level, and progressive bicytopenia ﬁnally led to the
iagnosis of IVL. IVL is a rare subtype of lymphoma characterized
y proliferation of lymphoma cells into small vessels, particu-
arly capillaries and post-capillary venules, with no evidence of
xtravascular tumor or detectable circulating lymphoma cells in
he peripheral blood. Because of the rarity of the disease, the inci-
ence rate and prognosis are unknown. IVL usually presents with
ymptoms related to involvement of skin and central nervous sys-
em [2–4]. However, the clinical features of IVL are considerably
aried and antemortem diagnosis is sometimes difﬁcult [5]. Previ-
us reports stated that constitutional B symptoms (i.e. fever, night
weats, and weight loss) are observed in most of the cases (55–85%)
2,6,7], however, our case did not show any of those symptoms. The
iagnosis of IVL requires detecting lymphoma cells within small to
edium sized blood vessels [8]. The treatment of IVL is chemother-
py with regimens used for the treatment of diffuse large B-cell
ymphoma. In our case, R-COP, a combination of recombinant anti-
D20 antibody, cyclophosphamide, vincristine, and prednisolone,
as used according to the standard regimen of malignant lym-
homa. Considering the safety concern of adverse cardiac effects
f doxorubicin, the drug was not included in the treatment. After
he initial treatment, despite no remarkable change in the chest
-ray, her symptoms showed improvement accompanied by the
eduction of TR-PG and normalization of serum LDH level. It is
ot fully determined whether PH in our case was truly caused by
nﬁltration of lymphoma cells into pulmonary vessels. Lung biopsy
as not performed, lymphoma cells were not detected from blood
n the pulmonary vessels, and the diagnosis was  based on the
emonstration of lymphoma cells by skin biopsy. However, both
ung biopsy and repeated right heart catheterization were consid-
rably invasive due to the poor general condition of the patient.
oreover, initial treatment with R-COP therapy for IVL was con-
idered to be effective judging from improvement of her symptoms
[y Cases 7 (2013) e181–e183 e183
and normalization of LDH accompanied by the reduction of PH
by echocardiography. Therefore, the inﬁltration of lymphoma cells
into pulmonary vessels was highly suspected to be the cause of PH,
although the direct relationship was  not elucidated. There are a
lot of underlying diseases that cause PH, therefore multiple exam-
inations are required to conﬁrm the cause. In patients with an
underlying cause of PH, treatments for both PH and the underlying
conditions are required. When the standard therapy for PH is not
effective, we  should seek other potential causes of PH and have to
reconstruct the treatment strategy. IVL may  potentially be added
as a differential diagnosis causing PH, although the prevalence is
low.
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